Mol Clifford D, Lim Kheng B, Sridhar Vandana, Zou Hua, Chien Ellen Y T, Sang Bi-Ching, Nowakowski Jacek, Kassel Daniel B, Cronin Ciarán N, McRee Duncan E
Syrrx, Inc., San Diego, California 92121, USA.
J Biol Chem. 2003 Aug 22;278(34):31461-4. doi: 10.1074/jbc.C300186200. Epub 2003 Jun 24.
The c-Kit proto-oncogene is a receptor protein-tyrosine kinase associated with several highly malignant human cancers. Upon binding its ligand, stem cell factor (SCF), c-Kit forms an active dimer that autophosphorylates itself and activates a signaling cascade that induces cell growth. Disease-causing human mutations that activate SCF-independent constitutive expression of c-Kit are found in acute myelogenous leukemia, human mast cell disease, and gastrointestinal stromal tumors. We report on the phosphorylation state and crystal structure of a c-Kit product complex. The c-Kit structure is in a fully active form, with ordered kinase activation and phosphate-binding loops. These results provide key insights into the molecular basis for c-Kit kinase transactivation to assist in the design of new competitive inhibitors targeting activated mutant forms of c-Kit that are resistant to current chemotherapy regimes.
c-Kit原癌基因是一种与多种高度恶性人类癌症相关的受体蛋白酪氨酸激酶。c-Kit与其配体干细胞因子(SCF)结合后,形成一个活性二聚体,该二聚体自身发生自磷酸化,并激活一个诱导细胞生长的信号级联反应。在急性髓性白血病、人类肥大细胞病和胃肠道间质瘤中发现了导致c-Kit非依赖SCF的组成型表达激活的致病人类突变。我们报道了一种c-Kit产物复合物的磷酸化状态和晶体结构。c-Kit结构处于完全活性形式,具有有序的激酶激活环和磷酸盐结合环。这些结果为c-Kit激酶反式激活的分子基础提供了关键见解,有助于设计针对对当前化疗方案耐药的c-Kit激活突变形式的新型竞争性抑制剂。